Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Monitoring of melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

ABSTRACT: Monitoring of melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

PROVIDER: PRJNA1093371 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28496483_1.fastq.gz	Fastqsanger.gz
	SRR28496483_2.fastq.gz	Fastqsanger.gz
	SRR28496484_1.fastq.gz	Fastqsanger.gz
	SRR28496484_2.fastq.gz	Fastqsanger.gz
	SRR28496485_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

Project description:Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

| PRJNA956565 | ENA

Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

Project description:Although treatment of melanoma patients with BRAF and MEK inhibitors has demonstrated impressive clinical outcomes, innate or acquired resistance to targeted therapy remains a major challenge. To uncover resistance mechanisms in patients, we performed single cell RNA sequencing of longitudinal biopsies of the same tumors from four consenting melanoma patients before the start of BRAFi/MEKi treatment and at different time points during treatment. Among the genes most differentially expressed between malignant cells from resistant vs. responding patients was POSTN encoding the secreted factor periostin. POSTN was predicted to predominantly signal to a macrophage population associated with targeted therapy resistance (TTR) in patients and was able to polarize macrophages towards a TTR phenotype. Finally, polarized TTR macrophages protected melanoma cells from MEKi-induced killing, which involved CD44 receptor expression on melanoma cells. Thus, interfering with the protective activity of TTR macrophages might represent a strategy to overcome targeted therapy resistance in melanoma.

2023-12-01 | GSE229908 | GEO

Monitoring of melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

Project description:Resistance to targeted therapy remains a major clinical challenge in melanoma patients. To uncover resistance mechanisms, we performed single cell RNA sequencing of fine needle aspirates from resistant and responding tumors from melanoma patients before and during BRAFi/MEKi treatment. Among the genes most differentially expressed between malignant cells from resistant vs. responding tumors was POSTN encoding the secreted factor periostin. POSTN was predicted to predominantly signal to a macrophage population associated with targeted therapy resistance (TTR). Accordingly, tumors from patients with fast disease progression after targeted therapy exhibited high POSTN expression levels as well as high numbers of TTR macrophages, and POSTN was able to polarize macrophages towards a TTR phenotype. In a mouse model in vivo, POSTN expression protected melanoma from targeted therapy, which was associated with a phenotype change of intratumroal macrophages. Finally, polarized TTR macrophages protected melanoma cells from MEKi-induced killing through CD44 receptor expression on melanoma cells. Thus, interfering with the protective activity of TTR macrophages might represent a strategy to overcome resistance to targeted therapy in melanoma.

2024-05-08 | GSE262779 | GEO

Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance.

Project description:Resistance to targeted therapy remains a major clinical challenge in melanoma. To uncover resistance mechanisms, we perform single-cell RNA sequencing on fine-needle aspirates from resistant and responding tumors of patients undergoing BRAFi/MEKi treatment. Among the genes most prominently expressed in resistant tumors is POSTN, predicted to signal to a macrophage population associated with targeted therapy resistance (TTR). Accordingly, tumors from patients with fast disease progression after therapy exhibit high POSTN expression levels and high numbers of TTR macrophages. POSTN polarizes human macrophages toward a TTR phenotype and promotes resistance to targeted therapy in a melanoma mouse model, which is associated with a phenotype change in intratumoral macrophages. Finally, polarized TTR macrophages directly protect human melanoma cells from MEKi-induced killing via CD44 receptor expression on melanoma cells. Thus, interfering with the protective activity of TTR macrophages may offer a strategy to overcome resistance to targeted therapy in melanoma.

| S-EPMC11293307 | biostudies-literature

ctDNA sequencing for monitoring targeted therapy

Project description:Non-invasive molecular monitoring of tumour burden and clonal selection in response to targeted therapy.

| PRJEB9309 | ENA

Characterization of a macrophage population under the control of nerves in the gastrointestinal tract

Project description:Primary objectives: Characterization of the macrophage population subset that is modulated by enteric neurons Primary endpoints: Characterization of the macrophage population subset that is modulated by enteric neurons via RNA sequencing

| 2538227 | ecrin-mdr-crc

High Glucose Macrophage Exosomes Enhance Atherosclerosis by Driving Cellular Proliferation & Hematopoiesis

Project description:High Glucose Macrophage Exosomes Enhance Atherosclerosis by Driving Cellular Proliferation & Hematopoiesis

| PRJNA722061 | ENA

High Glucose Macrophage Exosomes Enhance Atherosclerosis by Driving Cellular Proliferation & Hematopoiesis

Project description:High Glucose Macrophage Exosomes Enhance Atherosclerosis by Driving Cellular Proliferation & Hematopoiesis

| PRJNA683920 | ENA

High Glucose Macrophage Exosomes Enhance Atherosclerosis by Driving Cellular Proliferation & Hematopoiesis

Project description:High Glucose Macrophage Exosomes Enhance Atherosclerosis by Driving Cellular Proliferation & Hematopoiesis

| PRJNA722060 | ENA

The lung protective effect of driving pressure-guided pulmonary protective ventilation combined deep neuromuscular block in patients undergoing laparoscopic surgery for colorectal cancer

Project description:Intervention group:driving pressure-guided pulmonary protective ventilation combined deep neuromuscular block;Control group:normal pulmonary ventilation combined normal neuromuscular block Primary outcome(s): Postoperative pulmonary complications;Muscle relaxation monitoring Study Design: Parallel

| 40239 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data